A study of 48 people with signs of moderate alcohol-use disorder found that those taking low doses of semaglutide, currently produced by Novo Nordisk (NVO), lead them to drink less alcohol, Bloomberg’s Jessica Nix reports, citing a publication in JAMA Psychiatry. The study found people on semaglutide, the generic name of Ozempic, for nine weeks saw significantly greater reductions in how much alcohol they drank, as well as cravings for alcohol, compared with people on a placebo.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk initiated with an Equal Weight at Morgan Stanley
- Genmab upgraded to Neutral from Underperform at Exane BNP Paribas
- Hims & Hers jumps ahead of controversial Super Bowl ad airing
- Novo Nordisk Executives Report Share Transactions in Compliance with Market Regulations
- Viking Therapeutics price target lowered to $70 from $120 at Maxim